Q3 Revenue Misses Estimates as Adjusted EBITDA Loss Widens to $9.8M
PRCT sits 21% above its 52-week low of $16.665 on elevated volume (2.3× avg).
Summary
Q3 revenue came in at $98.291 million against the $102.6 million IBES estimate, a miss of roughly 4%. The adjusted EBITDA loss of $9.822 million was far wider than the $5.68 million loss analysts expected, and net loss for the quarter was $26.516 million. Full-year guidance points to a 65% gross margin and an adjusted EBITDA loss of $35 million to $30 million, versus the $33.7 million loss consensus. The revenue shortfall combined with the deeper-than-expected cash burn is the key negative — the company is spending more to generate less top line than the Street modeled. This follows the August disclosure that CEO Larry Wood bought $498,315 of stock at $20.85, a purchase made well above today's $20.11 price.
At the time of this announcement, PRCT was trading at $20.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $16.67 to $38.11. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.